Liminal BioSciences is a global clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases with a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market (LMNL).
On October 15, 2021 the Company closed on the divestment of the remainder of its plasma-derived therapeutics business to focus solely on its small molecule therapeutics pipeline.
Investor Relations and Communications Manager